Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Adlai Nortye Ltd. American Depositary Shares (ANL)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: ANL (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $9
1 Year Target Price $9
| 0 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -45.17% | Avg. Invested days 19 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 61.83M USD | Price to earnings Ratio - | 1Y Target Price 9 |
Price to earnings Ratio - | 1Y Target Price 9 | ||
Volume (30-day avg) 1 | Beta - | 52 Weeks Range 1.10 - 3.89 | Updated Date 08/29/2025 |
52 Weeks Range 1.10 - 3.89 | Updated Date 08/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.62 |
Earnings Date
Report Date 2025-08-22 | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -1220.88% |
Management Effectiveness
Return on Assets (TTM) -32.84% | Return on Equity (TTM) -103.19% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 28147088 | Price to Sales(TTM) 31.87 |
Enterprise Value 28147088 | Price to Sales(TTM) 31.87 | ||
Enterprise Value to Revenue 3.81 | Enterprise Value to EBITDA - | Shares Outstanding 31236900 | Shares Floating 59847067 |
Shares Outstanding 31236900 | Shares Floating 59847067 | ||
Percent Insiders 14.25 | Percent Institutions 0.19 |
Upturn AI SWOT
Adlai Nortye Ltd. American Depositary Shares
Company Overview
History and Background
Adlai Nortye Ltd. is a biopharmaceutical company focused on the discovery and development of innovative medicines for cancer. Founded in 2004, it has grown from a research-focused entity to a clinical-stage company with a global presence. They achieved significant milestones in clinical trial advancements for their lead drug candidates.
Core Business Areas
- Drug Discovery and Development: Focuses on identifying and developing novel cancer therapies.
- Clinical Trials: Conducts clinical trials to evaluate the safety and efficacy of their drug candidates.
- Commercialization: Prepares for the commercialization of approved drugs through partnerships and internal infrastructure.
Leadership and Structure
The company is led by a team of experienced biopharmaceutical executives and scientists. The organizational structure includes research and development, clinical operations, and commercial divisions.
Top Products and Market Share
Key Offerings
- AN2025: A selective inhibitor of histone deacetylase 6 (HDAC6) for the treatment of various cancers. Currently in clinical development. Market share data is not yet available. Competitors include companies developing HDAC inhibitors like Merck (Vorinostat) and Novartis (Farydak).
- AN0025: A potent and selective oral small molecule inhibitor of bromodomain and extraterminal (BET) proteins. Currently in clinical development for cancer. Market share data not yet available. Competitors include companies developing BET inhibitors such as Constellation Pharmaceuticals (acquired by MorphoSys).
Market Dynamics
Industry Overview
The biopharmaceutical industry is highly competitive, with companies racing to develop innovative therapies for various diseases. The oncology segment is particularly active due to the high unmet medical need.
Positioning
Adlai Nortye Ltd. is positioned as an innovative biopharmaceutical company with a focus on developing novel cancer therapies. Their competitive advantage lies in their differentiated drug candidates and experienced research team.
Total Addressable Market (TAM)
The global oncology market is estimated at over $200 billion. Adlai Nortye is positioned to capture a portion of this TAM with successful development and commercialization of their pipeline assets.
Upturn SWOT Analysis
Strengths
- Innovative drug pipeline
- Experienced management team
- Strong focus on oncology
- Global presence
Weaknesses
- Limited commercialization experience
- Reliance on clinical trial success
- Dependence on funding
- High R&D costs
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion into new markets
- Acquisition of new technologies
- Advancement of drug candidates through clinical trials
Threats
- Regulatory hurdles
- Competition from established pharmaceutical companies
- Clinical trial failures
- Economic downturns
Competitors and Market Share
Key Competitors
- MRK
- NVS
- MOR
Competitive Landscape
Adlai Nortye faces competition from established pharmaceutical companies with greater resources and established products. Their success depends on the differentiation and efficacy of their drug candidates.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is difficult to assess due to limited publicly available financial data.
Future Projections: Future growth is dependent on the successful development and commercialization of their drug candidates. Analyst estimates may vary, but expect growth with positive news.
Recent Initiatives: Recent initiatives include advancing clinical trials for AN2025 and AN0025 and seeking partnerships for commercialization.
Summary
Adlai Nortye is a biopharmaceutical firm in the clinical stage which focuses on creating novel cancer therapies. Their future relies on successfully developing and commercializing their drug candidates; therefore it is high risk. They lack commercial experience and face intense competition from better resourced pharma companies. Successful clinical trials are crucial for their prospects.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings (if available)
- Industry Reports
- Analyst Reports
Disclaimers:
This analysis is based on limited publicly available information and should not be considered investment advice. Market share data is estimated. This is not financial advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Adlai Nortye Ltd. American Depositary Shares
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2023-09-29 | Co- Founder, CEO & Chairman Mr. Yang Lu | ||
Sector Healthcare | Industry Biotechnology | Full time employees 123 | Website https://www.adlainortye.com |
Full time employees 123 | Website https://www.adlainortye.com | ||
Adlai Nortye Ltd., a clinical-stage biotechnology company, engages in the research and development of pharmaceutical products. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trials for the treatment of recurrent or metastatic head and neck squamous cell carcinomas. The company is also developing AN0025, a small molecule prostaglandin E receptor 4 antagonist to modulate the tumor microenvironment that is in a Phase Ib clinical trial for the treatment of recurrent non-small cell lung cancer and urothelial cancer after anti-PD-1/PD-L1 treatments, recurrent triple-negative breast cancer, microsatellite stable colorectal cancer, and cervical cancer after standard of care treatments; and AN4005, an oral small-molecule PD-L1 inhibitor, which is in Phase I clinical trials to induce and stabilize PD-L1 dimerization and disrupt the interaction between PD-1 and PD-L1. Its preclinical candidates include AN8025, a multifunctional antibody as T cell and antigen-presenting cell modulator; and AN9025, an oral small molecule pan-KRAS inhibitor. The company was founded in 2004 and is based in Grand Cayman, the Cayman Islands.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.